**Author Listing - Lead/ Submitting Author (we will be communicating with this individual): Name, Institution, City and State where the work was done. Co-authors will be added in a separate section.**
Atsushi Fukunari, Department of Amyloidosis Research,Nagasaki International University,Huis Ten Bosch Sasebo, Nagasaki　859-3298, Japan

**Main Body of the Abstract**
Transthyretin (TTR) is an amyloidogenic protein associated with wild-type TTR (ATTRwt) amyloidosis and hereditary TTR (ATTRv) amyloidosis. Dissociation of the tetramer of TTR to the monomer causes TTR misfolding, which results in amyloid fibril formation. Stabilizers of tetrameric TTR were proposed as effective therapeutic agents to delay disease progression. However, the established drugs are more expensive and cannot be used as a prophylactic measure. Our study aimed to find a prophylactic supplement to prevent TTR amyloid formation. We investigated arginine to see whether it could stabilize tetrameric TTR and thereby inhibit amyloid fibril formation. We analyzed amyloidogenicity with a thioflavin T method and evaluated changes in the forms of TTR by western blot. The thioflavin T method showed that in the presence of arginine, the values were significantly suppressed compared with those without arginine. Western blot showed that arginine mixed with recombinant ATTRwt and ATTR V30M reduced the monomer level and increased the tetramer/monomer ratio of TTR compared with samples without arginine. In addition, arginine mixed with human serum samples increased the tetramer/monomer ratio of TTR compared with samples without arginine. Moreover, orally administered arginine to healthy volunteers effectively increased the serum arginine concentration and the tetramer/monomer ratio of TTR in serum. Our results suggest that arginine prevents TTR amyloid formation and stabilizes the tetrameric conformation. Because arginine is a safe substance and a commonly used supplement, it may be a promising supplement for prophylactic use to prevent amyloid fibril formation in ATTRwt amyloidosis and ATTRv amyloidosis.



Arginine, as a possible amino acid for prevention of ATTR amyloidosis PC111 (#196)

We invite you to attend the XIX International Symposium on Amyloidosis to be held in Rochester, MN.

This symposium is organized as a hybrid meeting (with the focus on in-person) held from Sunday, May 26 through Thursday, May 30, 2024.

Together with the ISA Board and members of Mayo Clinic, a very attractive scientific hybrid program is being planned. The program will cover a variety of types of systemic amyloidosis: ATTR (hereditary and wild-type), AL (light-chain), AA and less frequent forms. There will be key lectures, specific symposia including those company sponsored, oral presentations and poster sessions of accepted abstracts.

COURSE DESCRIPTION
This program will provide a comprehensive review of state-of-the-art education in systemic amyloidosis: basic science, pathophysiology, diagnosis, current and emerging treatments. Scientific presentations will include competitive oral and poster abstracts. The rapid evolution of scientific discovery and expanding treatment options has created tremendous interest in the field and this meeting will fill and important gap in educating scientists and clinicians.